SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-084970
Filing Date
2023-11-09
Accepted
2023-11-09 09:18:41
Documents
73
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0923_jasperthera.htm   iXBRL 10-Q 954822
2 CERTIFICATION f10q0923ex31-1_jasperthera.htm EX-31.1 10432
3 CERTIFICATION f10q0923ex31-2_jasperthera.htm EX-31.2 10072
4 CERTIFICATION f10q0923ex32-1_jasperthera.htm EX-32.1 6250
  Complete submission text file 0001213900-23-084970.txt   5302444

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20230930.xsd EX-101.SCH 60314
6 XBRL CALCULATION FILE jspr-20230930_cal.xml EX-101.CAL 40553
7 XBRL DEFINITION FILE jspr-20230930_def.xml EX-101.DEF 254915
8 XBRL LABEL FILE jspr-20230930_lab.xml EX-101.LAB 502953
9 XBRL PRESENTATION FILE jspr-20230930_pre.xml EX-101.PRE 272727
67 EXTRACTED XBRL INSTANCE DOCUMENT f10q0923_jasperthera_htm.xml XML 624877
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 231390341
SIC: 2836 Biological Products, (No Diagnostic Substances)